Search

Radical prostatectomy is a standard surgical strategy for prostate cancer though with a few postoperative complications such as urinary incontinence, erectile dysfunction and vesicle urethral anastomotic stricture. Post-prostatectomy incontinence, as a common complication seriously affecting the patient's quality of life, is mainly diagnosed according to the clinical symptoms and the results of urodynamic and imaging examinations. Patients with post-prostatectomy incontinence may undergo corresponding anatomic and functional changes, which can be clearly and directly observed in imaging examination. This review focuses on the advances in the imaging studies of post-prostatectomy urinary incontinence from the perspectives of MRI, ultrasound and cystourethrography.

To evaluate the efficacy of Huang'e Capsules in the treatment of BPH of the qi-deficiency blood-stasis and damp-heat stagnation type under conditions of extensive use.Totally, 605 male patients with BPH of the qi-deficiency blood-stasis and damp-heat stagnation type received oral Huang'e Capsules, tid, 4 capsules per time, for 42 days. We recorded the IPSS, maximum urinary flow rate (Qmax), mean urinary flow rate (Qave), quality of life (QOL) score, and prostate volume of the patients before and after medication.A total of 503 patients completed the whole trial. Compared with the baseline, the patients showed significant decreases after treatment in the IPSS (20.1 ± 5.5 vs 12.6 ± 5.0, P0.05), QOL score (4.19 ± 0.90 vs 2.50 ± 0.89, P0.05) and prostate volume (［36.6 ± 15.8］ vs ［34.0 ± 17.6］ ml, P0.05), but remarkable increases in Qmax (［12.2 ± 5.8］ vs ［14.2 ± 6.5］ ml/s, P0.05) and Qave (［5.91 ± 3.12］ vs ［6.95 ± 3.45］ ml/s, P0.05).Huang'e Capsules had a good therapeutic effect on BPH of the qi-deficiency blood-stasis and damp-heat stagnation type.

To assess the clinical efficacy of the saw palmetto fruit extract (SPFE) in the treatment of lower urinary tract symptoms (LUTS) in patients with type ⅢA prostatitis.This retrospective study included 54 cases of type ⅢA prostatitis treated in the Outpatient Department of our hospital from January to December 2015. The patients were aged 35.06 ± 5.85 years, with a mean disease course of 3.8 ± 2.1 years, and all received oral medication of SPFE Capsules at the dose of 320 mg qd for 12 weeks. We assessed the therapeutic effects by comparing the NIH-chronic prostatitis symptom indexes (NIH-CPSI), voiding diary, International Prostate Symptom Scores (IPSS), and results of urodynamic examination before and after treatment.Compared with the baseline, both NIH-CPSI and IPSS were significantly decreased after medication (27.61 ± 3.76 vs 18.6 ± 5.34, P0.01; 20.44 ± 4.51 vs 10.96±4.62, P0.01), and urodynamic examination and voiding diary showed dramatic post-medication improvement in the average urinary flow rate (［8.05±1.42］ vs ［12.05±2.60］ ml/s, P0.01 ), maximum urinary flow rate (［14.22±1.74］ vs ［21.32±4.51］ ml/s, P0.01), residual urine volume (［46.15±16.57］ vs ［14.55±10.21］ ml, P0.01), maximum urethral closure pressure (［76.52±3.53］ vs ［65.32±4.75］ cm H2O, P0.01), mean urinary volume (［124.63±40.55］ vs ［285.93±58.68］ ml, P0.01), urination frequency (16.96±4.17 vs 8.96±2.50, P0.01), and nocturia frequency (8.94±3.23 vs 3.15±1.90, P0.01). No apparent adverse reactions were observed in any of the patients.SPFE Capsules can safely and effectively improve LUTS and thus the quality of life of patients with type ⅢA prostatitis.目的： 探讨锯叶棕果实提取物对以下尿路症状（LUTS）为主要症状的ⅢA型前列腺炎治疗的临床疗效。方法： 对2015年1月至12月就诊的54例ⅢA型前列腺炎患者予以锯叶棕果实提取物软胶囊口服320 mg/次，1次/d，12周后评价疗效。使用慢性前列腺炎症状指数（NIH-CPSI）评分、排尿日记及国际前列腺症状（IPSS）评分评估治疗前后症状，并行尿动力学检查，比较患者治疗前后变化。结果： 治疗12周后，患者的NIH-CPSI评分（18.6±5.34）较治疗前（27.61±3.76）明显下降（P0.01）、IPSS评分（10.96±4.62）较治疗前（20.44±4.51）有明显下降（P0.01）。尿动力学检查指标反应治疗前平均尿流率［AFR(8.05±1.42) ml/s］、最大尿流率［MFR(14.22±1.74) ml/s］、残余尿［RU(46.15±16.57) ml］、尿道最大闭合压［MCP(76.52±3.53) cmH2O］，治疗后指标［AFR(12.05±2.60) ml/s、MFR(21.32±4.51) ml/s、RU(14.55±10.21) ml、MCP(65.32±4.75) cmH2O］均明显改善（P0.01）。排尿日记显示治疗后平均排尿量［（285.93±58.68) ml］、排尿次数（8.96±2.50）及夜尿次数（3.15±1.90）次均较治疗前［（124.63±40.55) ml、16.96±4.17、8.94±3.23］明显改善（P0.01）。治疗期间所有患者均未诉不良反应。结论： 锯叶棕果实提取物可有效地改善ⅢA型前列腺炎患者出现的LUTS，提高患者生活质量，且安全性高，可作为临床治疗方案之一。.

To assess the efficacy and safety of Saw Palmetto Extract Capsules in the treatment of benign prostatic hyperplasia (BPH).We conducted a multi-centered open clinical study on 165 BPH patients treated with Saw Palmetto Extract Capsules at a dose of 160 mg qd for 12 weeks. At the baseline and after 6 and 12 weeks of medication, we compared the International Prostate Symptom Scores (IPSS), prostate volume, postvoid residual urine volume, urinary flow rate, quality of life scores (QOL), and adverse events between the two groups of patients.Compared with the baseline, both IPSS and QOL were improved after 6 weeks of medication, and at 12 weeks, significant improvement was found in IPSS, QOL, urinary flow rate, and postvoid residual urine. Mild stomachache occurred in 1 case, which necessitated no treatment.Saw Palmetto Extract Capsules were safe and effective for the treatment of BPH.